Mehmet Evren Okur, Androulla N Miliotou, Vasiliki Nitsola, Ioannis D Karantas, Neslihan Üstündağ Okur, Panoraia I Siafaka
{"title":"Current Situation on Diabetes Management: New Weapons Fighting the Disease in 2025.","authors":"Mehmet Evren Okur, Androulla N Miliotou, Vasiliki Nitsola, Ioannis D Karantas, Neslihan Üstündağ Okur, Panoraia I Siafaka","doi":"10.2174/0113894501399175250916110738","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The global prevalence of Diabetes Mellitus is rising; this complex metabolic disorder marked with hyperglycemia comes with increased morbidity and more associated health risks. Type 1 Diabetes Mellitus, an autoimmune disorder primarily affecting young individuals, lacks innovative pharmacological therapies. While current treatments for Type 2 Diabetes Mellitus-including lifestyle interventions and medications-can be effective, many patients still struggle with glycemic control. This review aims to highlight recent advances in diabetes mellitus management, emphasizing novel therapeutics and drug delivery systems that aim to decrease dosage frequency, target the manifestation of side effects, and enhance anti-diabetic effectiveness.</p><p><strong>Methods: </strong>We conducted a comprehensive review of over 300 articles published between 2017 and 2025, utilizing databases such as PubMed and ScienceDirect.</p><p><strong>Results: </strong>Recent therapeutic innovations include nanocarrier-mediated drug delivery, microneedle patches, and mRNA- and gene-based systems.</p><p><strong>Discussions: </strong>These technologies aim to improve glycemic control, reduce dosing frequency, and minimize side effects. The 2024 American Diabetes Association Standards of Care introduced updated diagnostic criteria and management recommendations, which are summarized herein.</p><p><strong>Conclusion: </strong>This review outlines key developments in pharmacological and delivery strategies of the past 5 years, targeting all types of diabetes. Special focus is placed on emerging therapies such as mRNA, nanotechnology, and innovative delivery systems, which may transform future diabetes management. The content is designed to support clinicians, researchers, and healthcare professionals in developing future therapeutic strategies.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501399175250916110738","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The global prevalence of Diabetes Mellitus is rising; this complex metabolic disorder marked with hyperglycemia comes with increased morbidity and more associated health risks. Type 1 Diabetes Mellitus, an autoimmune disorder primarily affecting young individuals, lacks innovative pharmacological therapies. While current treatments for Type 2 Diabetes Mellitus-including lifestyle interventions and medications-can be effective, many patients still struggle with glycemic control. This review aims to highlight recent advances in diabetes mellitus management, emphasizing novel therapeutics and drug delivery systems that aim to decrease dosage frequency, target the manifestation of side effects, and enhance anti-diabetic effectiveness.
Methods: We conducted a comprehensive review of over 300 articles published between 2017 and 2025, utilizing databases such as PubMed and ScienceDirect.
Results: Recent therapeutic innovations include nanocarrier-mediated drug delivery, microneedle patches, and mRNA- and gene-based systems.
Discussions: These technologies aim to improve glycemic control, reduce dosing frequency, and minimize side effects. The 2024 American Diabetes Association Standards of Care introduced updated diagnostic criteria and management recommendations, which are summarized herein.
Conclusion: This review outlines key developments in pharmacological and delivery strategies of the past 5 years, targeting all types of diabetes. Special focus is placed on emerging therapies such as mRNA, nanotechnology, and innovative delivery systems, which may transform future diabetes management. The content is designed to support clinicians, researchers, and healthcare professionals in developing future therapeutic strategies.
期刊介绍：
Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.
Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies.
As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
